Key result
ACEIs or ARBs reduce new-onset AF by ~30% in patients with heart failure.
Why the study?
More than 50 % of patients with permanent AF have a concurrent diagnosis of HF, and this combination increases hospital admissions, hospital stays, and overall mortality.
Answers are grounded in this paper and cite their sources.
Supports guideline-directed ACEI/ARB use in HF to curb new AF; leaves open dedicated RCTs on integrated anticoagulation strategies.
Atrial fibrillation (AF) and heart failure (HF) are global epidemics that began more than a century ago, and their association with an ageing general population has brought about an increase in cardiovascular morbidity and rising healthcare costs.1,2 More than 50 % of patients with permanent AF have a concurrent diagnosis of HF and this proportion is expected to rise.3 It is well established that the detrimental impact of AF in patients with HF results in a greater number of hospital admissions, longer hospital stays and an overall increase in mortali
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2016) conducted an editorial in Atrial fibrillation and concomitant heart failure. Guideline-directed heart failure medical therapy (ACEIs, ARBs, beta-blockers, MRAs) and oral anticoagulation (NOACs or VKAs) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: